Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19

Maslennikov, Roman; Ивашкин, В. Т.; Vasilieva, Ekaterina; Chipurik, Maxim; Semikova, Polina; Semenets, Victoria; Russkova, Tatyana; Levshina, Anna; Grigoriadis, Diana; Magomedov, Shamil; Efremova, Irina; Dzhakhaya, Natiya

doi:10.1016/j.pupt.2021.102039

Cited by 40 publications

(31 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Experimental and clinical evidence on autoinflammatory diseases, even those that are rare, has proved to be extremely useful in addressing the health emergency of the pandemic caused by COVID-19, even simply in preventing/limiting the cascade effects of hyper inflammation and cytokine storms [ 194 , 195 , 196 , 197 , 198 ].…”

Section: Discussionmentioning

confidence: 99%

Autoinflammatory Diseases and Cytokine Storms—Imbalances of Innate and Adaptative Immunity

Marcuzzi

Melloni

Zauli

et al. 2021

IJMS

View full text Add to dashboard Cite

Innate and adaptive immune responses have a well-known link and represent the distinctive origins of several diseases, many of which may be the consequence of the loss of balance between these two responses. Indeed, autoinflammation and autoimmunity represent the two extremes of a continuous spectrum of pathologic conditions with numerous overlaps in different pathologies. A common characteristic of these dysregulations is represented by hyperinflammation, which is an exaggerated response of the immune system, especially involving white blood cells, macrophages, and inflammasome activation with the hyperproduction of cytokines in response to various triggering stimuli. Moreover, hyperinflammation is of great interest, as it is one of the main manifestations of COVID-19 infection, and the cytokine storm and its most important components are the targets of the pharmacological treatments used to combat COVID-19 damage. In this context, the purpose of our review is to provide a focus on the pathogenesis of autoinflammation and, in particular, of hyperinflammation in order to generate insights for the identification of new therapeutic targets and strategies.

show abstract

Section: Discussionmentioning

confidence: 99%

Autoinflammatory Diseases and Cytokine Storms—Imbalances of Innate and Adaptative Immunity

Marcuzzi

Melloni

Zauli

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Its predictable pharmacokinetics and lack of immunogenicity suggest good efficacy and safety. [ 4 5 ]…”

Section: Discussionmentioning

confidence: 99%

“…[ 7 ] A retrospective study by Maslennikov et al . [ 5 ] has shown that mortality and the incidence of admission to ICU were lower in the tofacitinib group than in the control group ( P = 0.009 and P = 0.004). Further, there was a marked improvement in oxygen saturation ( P = 0.012), decrease in CRP ( P = 0.048) as well as the number of patients requiring mechanical ventilation ( P = 0.020) in the tofacitinib group than in the control group, 7–10 days after starting tofacitinib administration.…”

Section: Discussionmentioning

confidence: 99%

Tofacitinib as a novel therapy in COVID-19 acute respiratory distress syndrome

Singh

Panda

Kodamanchili

et al. 2021

Indian Journal of Anaesthesia

View full text Add to dashboard Cite

“…Similar to Baricitinib, the JAK inhibitor Tofacitinib is also approved as an anti-rheumatic drug (192). When applied to COVID-19 patients with high levels of CRP within the TOFA-COV-2 trial, Tofacitinib treatment lowered the lung damage and CRP levels, increased the oxygen saturation and thus was suggested as an effective medication for managing the cytokine levels during COVID-19 (193)…”

Section: Jak Inhibitorsmentioning

confidence: 99%

Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics

et al. 2021

View full text Add to dashboard Cite

Since November 2019 the SARS-CoV-2 pandemic has caused nearly 200 million infection and more than 4 million deaths globally (Updated information from the World Health Organization, as on 2nd Aug 2021). Within only one year into the pandemic, several vaccines were designed and reached approval for the immunization of the world population. The remarkable protective effects of the manufactured vaccines are demonstrated in countries with high vaccination rates, such as Israel and UK. However, limited production capacities, poor distribution infrastructures and political hesitations still hamper the availability of vaccines in many countries. In addition, due to the emergency of SARS-CoV-2 variants with immune escape properties towards the vaccines the global numbers of new infections as well as patients developing severe COVID-19, remains high. New studies reported that about 8% of infected individuals develop long term symptoms with strong personal restrictions on private as well as professional level, which contributes to the long socioeconomic problems caused by this pandemic. Until today, emergency use-approved treatment options for COVID-19 are limited to the antiviral Remdesivir, a nucleoside analogue targeting the viral polymerase, the glucocorticosteroide Dexamethasone as well as neutralizing antibodies. The therapeutic benefits of these treatments are under ongoing debate and clinical studies assessing the efficiency of these treatments are still underway. To identify new therapeutic treatments for COVID-19, now and by the post-pandemic era, diverse experimental approaches are under scientific evaluation in companies and scientific research teams all over the world. To accelerate clinical translation of promising candidates, repurposing approaches of known approved drugs are specifically fostered but also novel technologies are being developed and are under investigation. This review summarizes the recent developments from the lab bench as well as the clinical status of emerging therapeutic candidates and discusses possible therapeutic entry points for the treatment strategies with regard to the biology of SARS-CoV-2 and the clinical course of COVID-19.

show abstract

Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19

Cited by 40 publications

References 12 publications

Autoinflammatory Diseases and Cytokine Storms—Imbalances of Innate and Adaptative Immunity

Autoinflammatory Diseases and Cytokine Storms—Imbalances of Innate and Adaptative Immunity

Tofacitinib as a novel therapy in COVID-19 acute respiratory distress syndrome

Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics

Contact Info

Product

Resources

About